PresseKat - Russian Investors attracted by European Healthcare business!

Russian Investors attracted by European Healthcare business!

ID: 588378

(firmenpresse) - More and more Russian investors and Pharma companies are interested in West- European healthcare and Pharma / OTC targets. Nowadays the CIS and CEE Pharma markets develop very well, mostly above 15-17%. However the markets are still dominated by more than 80% imported products from West-Europe, Asia and the US. Will this change? What will change? We at Chameleon Pharma Consulting notice that more and more Russian, Ukrainian, Polish and Kazak investors and Pharma
cooperations are interested to acquire healthcare or pharmaceutical products and
companies in Western Europe. Some players like the Slovenian KRKA Group have already made a move towards “west” some years ago. They bought the German Pharma company TAD in the North of the country. Others Russian investors are currently on “a Pharma & Medical company target shopping tour” in Europe.

However Russian investors seam to be “slow movers” to invest into Medical or Pharma companies in Europe. This may happen due to the lack of market knowledge or other reasons. “Howerver such investments in Europe could definitely bring innovative products and techniques to the Russian healthcare market and investors could benefit from long term stable profits”, say Reiner Christensen, the CEO of Chameleon Pharma Consulting.

“We, Chameleon Pharma Consulting, had many interesting discussions with Russian investors during last months, but Russian players need to be quicker in the due diligence execution”, says Andreas Masel, the Pharma veteran of Chameleon Pharma Consulting. US and Asian investors seem to be faster so far to decide on innovative healthcare investments in Europe and thus earn the advantages from these smart steps.

Andreas Masel adds, “I would recommend Russian investors, interested in Pharma and Medical assets, balancing their portfolio and acquiring more targets in West-
Europe. This could also bring good technologies to the CIS & CEE markets.”




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:

Chameleon Pharma Consulting is an export for Sales and Marketing, M & A, Distribution, Regulatory, R & D in the CIS region (Russia, Ukraine, Kazakhstan, Belarus etc.) and Eastern Europe(Poland, Rumania, Bulgaria etc.) and has a wide network with longstanding contacts. Chameleon Pharma Consulting is based close to the former airport Berlin Tempelhof in the heart of the German capital.



PresseKontakt / Agentur:

Olga Kiefer

Tel. 030 648 35164

olki(at)chameleon-pharma.com



drucken  als PDF  an Freund senden  Quintiles: Partner in allen Phasen des Produktlebenszyklus – für Lösungen aus einer Hand New innovative retail outlets“ supermarket combined with pharmacies” - opened in the suburbs of Moscow
Bereitgestellt von Benutzer: ChameleonPharma
Datum: 05.03.2012 - 15:51 Uhr
Sprache: Deutsch
News-ID 588378
Anzahl Zeichen: 1998

Kontakt-Informationen:
Ansprechpartner: Olga Kiefer
Stadt:

Halle


Telefon: 030 64825164

Kategorie:

Pharma


Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum: 05.03.12

Diese Pressemitteilung wurde bisher 0 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Russian Investors attracted by European Healthcare business!"
steht unter der journalistisch-redaktionellen Verantwortung von

Chameleon Pharma Consulting (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

CHAMELEON PHARMA CONSULTING auf der EXPOPHARM ...

Chameleon Pharama Consulting ist ein junges Unternehmen, das sich aber rasch als zuverlässiger und erfolgreicher Partner für die Markterweiterung im Gesundheitsbereich etabliert hat. 60 erfolgreich abgeschlossene Consulting-Projekte in den letzten ...

Polfarma increased its stake in Russian pharma company ...

The joint-stock company Polfarma Pharmaceutical Factory increased its stake in OJSC Integrated Chemical and Pharmaceutical Enterprise Akrikin from 72.54% to 98.17%. Akrikhin is the fifth largest local producer by revenue 2010 and one of the fastes ...

Alle Meldungen von Chameleon Pharma Consulting